A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands

Djamila E. Issa, Avinash G. Dinmohamed, Marielle J. Wondergem, Hedwig M. Blommestein, Peter C. Huijgens, Pieternella J. Lugtenburg, Otto Visser, Sonja Zweegman, Martine E.D. Chamuleau

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)


Randomized controlled trials have studied different dose-intensity and dose-interval regimens of R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL). This study was undertaken to confirm these results in a population-based setting, with special emphasis on the value of 6xR-CHOP21 among patients aged 18–64 years. Two thousand three hundred and thirty-eight stage II–IV DLBCL patients, ≥18 years, we confirmed the similar efficacy of six versus eight cycles of R-CHOP and of R-CHOP21 versus R-CHOP14 regimens across all age groups on overall survival (median follow-up 36.4 (1.3–167.6) months). Nevertheless, overall survival decreased with older age. Interestingly, in patients 18–64 years, the adjusted risk of mortality among recipients of 6xR-CHOP21 compared to other R-CHOP regimens seems to be similar (HR 0.62; 95%CI: 0.38–1.02; p= .059). Although this finding might suggest that 6xR-CHOP21 could be considered as first-line regimen for all stage II–IV DLBCL patients, it should be confirmed in forthcoming population-based studies with larger patient numbers and longitudinal follow-up.

Original languageEnglish
Pages (from-to)549-559
Number of pages11
JournalLeukemia and Lymphoma
Issue number3
Publication statusPublished - 2021


  • Diffuse large B-cell lymphoma
  • R-CHOP
  • population-based
  • survival

Cite this